Back to Startups

Insilico Medicine

About Insilico Medicine

Insilico Medicine is a biotechnology company that leverages artificial intelligence and machine learning to accelerate drug discovery and development. The company focuses on using advanced algorithms to identify potential drug candidates and optimize the drug development process, significantly reducing the time and cost associated with bringing new therapies to market.

Business Information
Target Customers
pharmaceutical companies biotech firms research institutions
Industry Categories
Bioscience & Disease Healthcare Systems AI, ML, Gen AI
Business Model
Revenue Model B2B partnerships and collaborations
Pricing Strategy Custom pricing based on project scope
Sales Channels direct sales, strategic partnerships
Funding Timeline
Round Date Amount Investors
Series D Jun 20, 2025 $255.0M Unknown
Series E Oct 04, 2023 $123.0M Unknown
Founders

No founder information available.

Investors

No investor information available.

Recent Mentions
chuminhua432
Minhua Chu @chuminhua432
Jun 16, 2025

Insilico Medicine today announced the recent completion of its Series E financing. With strong support from investors, the company raised approximately $123 million in this round, surpassing its original fundraising target. https://t.co/UuwxcFhjBm

Longevity0S
Longevity Decoded @Longevity0S
Jun 20, 2025

BREAKOUT SECTOR: AI-Driven Drug Discovery INSILICO MEDICINE: $255M Series D • AI discovers longevity targets in 18 months vs 6 years traditional • 30+ compounds in development • First AI-discovered anti-aging drug entering Phase 2 DEEP LONGEVITY: $14M seed round • AI